News Vector Science and Therapeutics Corp.

Stocks

PAIN

CA92244M1041

Investment Holding Companies

Market Closed - Toronto S.E. 19:59:35 27/10/2026 GMT			5-day change	1st Jan Change
1.640 ^CAD	+7.89%		+1.23%	+3,180.00%

10-22	Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides	CI
10-19	Vector Science and Therapeutics Corp. Announces Appointment of Angus Jackson as Managing Director of Corporate Development	CI

All News

Mentions Relevance

10-22	Vector Science and Therapeutics Corp. Introduces Peptide-Matrix Microneedle Technology for Targeted Transdermal Delivery of Peptides	CI
10-19	Vector Science and Therapeutics Corp. Announces Appointment of Angus Jackson as Managing Director of Corporate Development	CI
10-14	Vector Science & Therapeutics Corp. Announces the Appointment of Russell Starr as President of the Company, Effective October 5, 2026	CI
10-13	Vector Science and Therapeutics Corp. Announces Collaboration and Safe Investment in Whoopi Wellness, Inc	CI
10-12	Whoopi Wellness, Inc. announced that it has received funding from Vector Science and Therapeutics Corp.	CI
10-07	Scoreboard, Inc. announced that it has received funding from Vector Science and Therapeutics Corp.	CI
10-07	Vector Science and Therapeutics Corp. Announces Collaboration with SAFE Investment in Gary Payton's Scoreboard	AQ
10-07	Vector Science And Therapeutics Corp. Announces Collaboration With SAFE Investment In Scoreboard, Inc	CI
09-25	Vector Science and Therapeutics Corp. Issues Options	NE
08-26	Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options	AQ
08-24	Vector Science Starts Manufacturing Pharma-Grade Peptides	MT
08-24	Vector Science & Therapeutics Increases Peptide Manufacturing Capacity At Lyogenesis Facility	CI
08-24	Vector Science & Therapeutics Begins Peptide Production As First Suite At LyoGenesis Manufacturing Comes Online	CI
08-24	Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online	AQ
08-20	Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	AQ
08-20	Vector Science and Therapeutics Corp Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides	CI
08-19	/C O R R E C T I O N -- Vector Sciences & Therapeutics/	AQ
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings	AQ
08-17	Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement With LyoGenesis Holdings LLC	CI
07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-27	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-24	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28	AQ
07-24	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
07-21	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels	AQ
07-17	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist	CI